HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • HC-7366
    • HC-5404
    • Odetiglucan
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • HC-7366
    • HC-5404
    • Odetiglucan
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers

Publication Topic: HiberCell's Publications

Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors

Cancer immunotherapy via myeloid signaling pathway co-activation (Wattenberg et al. AACR Pancreatic Cancer 2022)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy

Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

Posts navigation

Older posts
Newer posts
HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • HC-7366
    • HC-5404
    • Odetiglucan
  • Pipeline
  • News & Publications
  • Contact
  • Careers
Linked In

© 2025 Hibercell Inc |
Privacy Policy |
Terms & Conditions |
Expanded Access